NASDAQ:VCYT - Veracyte Stock Price, Forecast & News

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Veracyte Inc (NASDAQ:VCYT) issued its quarterly earnings data on Tuesday, October, 22nd. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.05. The biotechnology company earned $30.97 million during the quarter, compared to analyst estimates of $30.41 million. Veracyte had a negative return on equity of 5.33% and a negative net margin of 7.08%. View Veracyte's Earnings History.

Veracyte is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Veracyte.

Veracyte issued an update on its FY 2019 earnings guidance on Tuesday, October, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $119-122 million, compared to the consensus revenue estimate of $120.14 million.

3 brokerages have issued 12 month price objectives for Veracyte's stock. Their forecasts range from $17.00 to $35.00. On average, they anticipate Veracyte's stock price to reach $28.67 in the next year. This suggests that the stock has a possible downside of 0.0%. View Analyst Price Targets for Veracyte.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veracyte.

Media headlines about VCYT stock have trended negative recently, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Veracyte earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Veracyte.

Veracyte saw a increase in short interest in the month of November. As of November 29th, there was short interest totalling 2,760,000 shares, an increase of 5.3% from the November 14th total of 2,620,000 shares. Based on an average trading volume of 641,800 shares, the short-interest ratio is currently 4.3 days. Currently, 6.1% of the shares of the stock are sold short. View Veracyte's Current Options Chain.

Some companies that are related to Veracyte include ELEKTA AB/ADR (EKTAY), Natera (NTRA), InVitae (NVTA), RadNet (RDNT), CareDx (CDNA), Castle Biosciences (CSTL), Personalis (PSNL), Fulgent Genetics (FLGT), DermTech (DMTK), Centogene (CNTG), Enzo Biochem (ENZ), Celcuity (CELC), Psychemedics (PMD), Miragen Therapeutics (MGEN) and PotNetwork (POTN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), BlackRock (BLK), Advanced Micro Devices (AMD), InVitae (NVTA), Netflix (NFLX), AbbVie (ABBV), Chipotle Mexican Grill (CMG) and Exelixis (EXEL).

Veracyte's stock is owned by a number of of institutional and retail investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (7.83%), Nikko Asset Management Americas Inc. (5.66%), Sumitomo Mitsui Trust Holdings Inc. (5.66%), State Street Corp (4.33%), Versant Venture Management LLC (2.49%) and Pictet Asset Management Ltd. (1.84%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr and Keith Kennedy. View Institutional Ownership Trends for Veracyte.

VCYT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Versant Venture Management LLC, Russell Investments Group Ltd., Calamos Advisors LLC, Gilder Gagnon Howe & Co. LLC, Castleark Management LLC, Essex Investment Management Co. LLC and Perkins Capital Management Inc.. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr and Keith Kennedy. View Insider Buying and Selling for Veracyte.

VCYT stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Pictet Asset Management Ltd., Nikko Asset Management Americas Inc., State Street Corp, KAMES CAPITAL plc, State of New Jersey Common Pension Fund D, Railway Pension Investments Ltd and Granahan Investment Management Inc. MA. View Insider Buying and Selling for Veracyte.

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VCYT stock can currently be purchased for approximately $28.68.

Veracyte has a market capitalization of $1.40 billion and generates $92.01 million in revenue each year. The biotechnology company earns $-23,000,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Veracyte employs 270 workers across the globe.View Additional Information About Veracyte.

The official website for Veracyte is http://www.veracyte.com/.

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]